Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
The first FDA-cleared device that supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our five FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without additional equipment, procedures or radiation dose.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
MIAMISBURG, Ohio (August 24, 2023) – Riverain Technologies, a medical device company revolutionizing chest imaging interpretation with Clear Visual Intelligence™ (CVI), announced today that Dayton VA Medical Center is now using ClearRead™ CT with CVI to more quickly and reliably detect lung cancer in veteran patients.
“Finding lung cancer early is vital to improving patient outcomes,” said Steve Worrell, CEO, Riverain Technologies. “ClearRead™ CT with Clear Visual Intelligence is a unique and proven solution that significantly improves the detection of pulmonary nodules, and we’re thrilled to provide this advanced technology for the care of our veterans in Dayton.”
ClearRead uses a unique suppression technology that goes beyond standard background-impaired imaging interpretation to reveal actionable nodules in chest imaging to detect pulmonary nodules accurately and quickly.
As the leader in thoracic imaging interpretation tools for pulmonary nodules, Riverain Technologies was selected to provide ClearRead CT to 22 VA hub locations and 87 spoke sites across the country, as part of the VA’s Lung Precision Oncology Program (LPOP). ClearRead CT was also recently deployed at the Pittsburgh and Fresno Medical Centers.
The Dayton VA Medical Center serves more than 40,000 veterans each year and is one of the oldest VAs in the nation. LPOP chose ClearRead CT to help improve the lung cancer survival rate for veterans across the U.S., which aligns with Riverain’s mission to eliminate delayed cardio-thoracic disease diagnoses.
Veterans are particularly at risk for lung cancer and suffer lower survival rates than the general population. Nearly 8,000 veterans are diagnosed with lung cancer each year. Detecting lung cancer in its earliest stages is the most effective route to treatments that improve survival rates.
ClearRead technology is a state-of-the-art approach utilizing the latest advances in deep learning. The advanced algorithm produces a vessel-suppressed series that aids the radiologist through the removal of the vascular structures and machine noise, allowing them to read the CT images faster and more accurately. Radiologists can then use ClearRead to view additional quantitative information when lesions are detected. ClearRead CT reduces missed nodules by 29% and reduces nodule search time by 26%.*
About Riverain Technologies
Riverain Technologies is on a mission to revolutionize radiology by eliminating delayed cardiothoracic disease diagnoses. Using a unique suppression technology, ClearRead solutions with CVI remove the interfering normal structures within the chest, like bones and vessels, and machine noise, which can compromise accurate and efficient diagnoses. This provides an unimpaired view that enables the radiologist to uniquely focus on the actionable data in chest imaging to precisely detect, characterize, and report findings to improve diagnostic accuracy and advance earlier intervention. For more information: https://www.riveraintech.com/.
*Lo, S. B., Freedman, M. T., Gillis, L. B., White, C. S., & Mun, S. K. (2018). JOURNAL CLUB: Computer-Aided Detection of Lung Nodules on CT With a Computerized Pulmonary Vessel Suppressed Function. American Journal of Roentgenology, 210(3), 480–488. doi: 10.2214/ajr.17.18718.
|cookielawinfo-checkbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checkbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|